Mice were fasted for 5 h at the beginning of the light cycle, and then intraperitoneally injected with 2 g of glucose per kg body weight
Red flag symptoms requiring urgent medical attention include: Severe, persistent abdominal pain , particularly in the upper abdomen or epigastric region, which could indicate pancreatitis (a rare but serious adverse effect of GLP-1 therapy) Difficulty swallowing (dysphagia) or painful swallowing (odynophagia) Unintentional weight loss beyond expected therapeutic effects Persistent vomiting that prevents adequate oral intake or medication administration Right upper quadrant pain, fever, or yellowing of skin/eyes , which could indicate gallbladder disease (a known risk with weight loss on GLP-1 therapies) Symptoms of gastroparesis such as early satiety, postprandial fullness, or vomiting undigested food Call 911 or seek emergency care immediately for: Severe chest pain that could represent cardiac pathology rather than reflux Evidence of gastrointestinal bleeding , including black, tarry stools or vomiting blood or coffee-ground material If you suspect pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without nausea/vomiting), stop taking the GLP-1 medication immediately and seek urgent medical care, as directed in FDA prescribing information
Your clothes might fit tighter
Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease
